Aztreonam and Avibactam
Brand names: Emblaveo · Active ingredient: Aztreonam, Avibactam
In short: EMBLAVEO, in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coli, K
What is Aztreonam and Avibactam used for?
EMBLAVEO, in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens. Approval of this indication is based on limited clinical safety and efficacy data for EMBLAVEO .
To reduce the development of drug-resistant bacteria and maintain the effectiveness of EMBLAVEO and other antibacterial drugs, EMBLAVEO should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Aztreonam and Avibactam dosage
Table 1 shows the recommended dosage to be administered by intravenous (IV) infusion over 3 hours in adults with estimated creatinine clearance (CLcr) greater than 50 mL/min.
Type of Infection | Recommended Doses for EMBLAVEO
(aztreonam and avibactam)
b | Dosing Interval
c | Treatment duration
Complicated intra-abdominal infections (cIAI)d | Loading | EMBLAVEO 2.67 g(aztreonam 2 grams and avibactam 0.67 grams) | Every 6 hours | 5 to 14 days
Maintenance | EMBLAVEO 2 g(aztreonam 1.5 grams and avibactam 0.5 grams)
aCalculated using the Cockcroft-Gault formula.
bAztreonam-avibactam is a combination product in a fixed 3:1 ratio. A single loading dose is followed by maintenance doses beginning at the next dosing interval.
cDosing interval is calculated from the start of one infusion to the start of the subsequent infusion.
dFor treatment of cIAI, administer metronidazole concurrently.
Table 2 shows the recommended dosage to be administered by intravenous (IV) infusion over 3 hours in adults with estimated creatinine clearance (CLcr) less than or equal to 50 mL/min. In patients with renal impairment, close monitoring of estimated CLcr is advised. In some patients, the CLcr estimated from serum creatinine can change quickly, especially early in the course of treatment for the infection. For treatment of cIAI, administer metronidazole concurrently.
Estimated CLcr (mL/min)
a | Recommended Dose for EMBLAVEO
(aztreonam and avibactam)
b,c | Dosing Interval
d
Greater than 30 to less than or equal to 50 mL/min | Loading | EMBLAVEO 2.67 g(aztreonam 2 grams and avibactam 0.67 grams) | Every 6 hours
Maintenance | EMBLAVEO 1 g(aztreonam 0.75 grams and avibactam 0.25 grams)
Greater than 15 to less than or equal to 30 mL/min | Loading | EMBLAVEO 1.8 g(aztreonam 1.35 grams and avibactam 0.45 grams) | Every 8 hours
Maintenance | EMBLAVEO 0.9 g(aztreonam 0.675 grams and avibactam 0.225 grams)
Less than or equal to 15, including on hemodialysise | Loading | EMBLAVEO 1.33 g(aztreonam 1 gram and avibactam 0.33 grams) | Every 12 hours
Maintenance | EMBLAVEO 0.9 g(aztreonam 0.675 grams and avibactam 0.225 grams)
aCalculated using the Cockcroft-Gault formula
bAztreonam-avibactam is a combination product in a fixed 3:1 ratio. A single loading dose is followed by maintenance doses beginning at the next dosing interval.
cThe total duration of treatment is for 5 days to 14 days.
dDosing interval is calculated from the start of one infusion to the start of the subsequent infusion.
eBoth aztreonam and avibactam are hemodialyzable; thus, administer EMBLAVEO after hemodialysis on hemodialysis days.
EMBLAVEO is supplied as a lyophilized powder, which must be reconstituted and subsequently diluted, using aseptic technique prior to intravenous infusion. …
How to take Aztreonam and Avibactam — instructions & advice from the label
Serious Allergic Reactions
Advise patients, their families, or caregivers that allergic reactions, including serious allergic reactions, could occur that require immediate treatment. Ask them about any previous hypersensitivity reactions to EMBLAVEO, other beta-lactams, or other allergens .
Serious Skin Reactions
Advise patients about the signs and symptoms of serious skin manifestations such as sudden onset of a severe rash or blistering or peeling skin, possibly accompanied by a high fever or joint pain (these may be signs of more serious medical conditions such as toxic epidermal necrolysis) .
Potentially Serious Diarrhea
Advise patients, their families, or caregivers that diarrhea is a common problem caused by antibacterial drugs. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, tell them to contact his or her healthcare provider .
Antibacterial
Resistance
Patients should be counseled that antibacterial drugs including EMBLAVEO should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). …
Warnings & precautions
Do not take this medicine if: EMBLAVEO is contraindicated in patients with known hypersensitivity to the components of EMBLAVEO (aztreonam and avibactam) .
Hypersensitivity reactions were noted in patients treated with EMBLAVEO, including rash, flushing, and bronchospasm .
Prior to treatment, it should be established if the patient has a history of hypersensitivity reactions to components of EMBLAVEO (aztreonam and avibactam). In case of hypersensitivity reactions, immediately discontinue EMBLAVEO and initiate appropriate medications and/or supportive care.
Cases of toxic epidermal necrolysis have been reported in association with aztreonam (a component of EMBLAVEO) in patients undergoing bone marrow transplant with multiple risk factors including sepsis, radiation therapy, and other concomitantly administered drugs associated with toxic epidermal necrolysis. Discontinue EMBLAVEO if a serious skin reaction occurs.
Elevations in hepatic transaminases have been observed during treatment with EMBLAVEO . Monitoring of liver-related laboratory tests is recommended while on treatment, particularly in patients with baseline liver comorbidities or on concomitant hepatotoxic medications. If transaminase elevations are noted, consider discontinuing EMBLAVEO, if clinically indicated, and monitor the patient for resolution of any pertinent clinical and laboratory findings.
Clostridioides difficile-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial drugs, including EMBLAVEO, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial drugs alters the normal flora of the colon and may permit overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. …
Aztreonam and Avibactam side effects
The following adverse reactions are discussed in greater detail in the Warnings and Precautions section:
Hypersensitivity Reactions
Serious Skin Disorders
Hepatic Adverse Reactions
Clostridioides Difficile-Associated Diarrhea
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience in Adult Patients
Three clinical trials, Trial 1, Trial 2, and Trial 3, underly the EMBLAVEO clinical development program. Trial 1 was a randomized, comparative trial conducted in patients with cIAI and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) (not an approved indication for EMBLAVEO), while Trials 2 and 3 were smaller, noncomparative trials conducted in patients with cIAI as well as other serious infections caused by gram negative pathogens expressing metallo-beta-lactamases. The safety data from Trial 1 are summarized below.
In Trial 1, EMBLAVEO was evaluated in a comparative clinical trial in patients with cIAI or HABP/VABP; note that EMBLAVEO is not approved for the treatment of HABP/VABP. …
Drug interactions
Concomitant use of organic anion transporter (OAT) 1 and OAT 3 transporter inhibitors (e.g., probenecid) with EMBLAVEO is not recommended. There is insufficient information to characterize the effect of concomitant use of OAT 1/3 transport inhibitors with EMBLAVEO .
About this medicine
EMBLAVEO for injection, for intravenous use, is a combination product consisting of aztreonam and avibactam sodium.
Aztreonam
Aztreonam is a synthetic, monobactam antibacterial drug. Its chemical name is (Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid. Its molecular weight is 435.43 g/mol. The empirical formula is C13H17N5O8S2.
Figure 1
.
Chemical structure of aztreonam
.
Avibactam
Avibactam sodium is a beta-lactamase inhibitor. Its chemical name is sodium [(2S,5R)-2-carbamoyl-7-oxo-1,6- diazabicyclo[3.2.1]octan-6-yl] sulfate. Its molecular weight is 287.23 g/mol. The empirical formula is C7H10N3O6SNa.
Figure 2. Chemical structure of avibactam sodium
.
EMBLAVEO 2 grams (aztreonam 1.5 grams and avibactam 0.5 grams) for injection is a white to slightly yellow sterile powder for reconstitution consisting of aztreonam and avibactam packaged in glass vials. The formulation also contains inactive ingredient L-arginine 1170 mg/vial. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID be1a6c99-d4b3-46d7-9e99-6e5f9fab556a. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin